Clinical trials: Bone Density, Low
Soy Isoflavone Effect, Bone Density, Low
Effects of Soy Isoflavone on Bone Health Among Saudi Female Students Imam Abdulrahman Bin Faisal University.
Low bone mineral density (BMD) has recently increased among young women. Soy Isoflavone as a food supplement, has been found to have potent effect on bone health in postmenopausal women.
- Conditions
- Soy Isoflavone Effect, Bone Density, Low, Bone Density Increased
- Trial name
- NCT04547010
- Testing
- Soy Isoflavone supplement
- Where
- Saudi Arabia
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Imam Abdulrahman Bin Faisal University
Low Bone Density
Age Related Changes in Calciotropic Hormones and Their Impact on Male Osteoporosis
The purpose of this pilot study is to generate preliminary data regarding the skeletal effects of age-related changes in calcium and vitamin D metabolism in older men.
- Trial name
- NCT00588874
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Yale University
Chronic Kidney Diseases, Fracture
Denosumab Treatment in CKD Patients at High Risk of Fracture
Objective: To verify the efficacy and safety of denosumab in the prevention and treatment of CKD-MBD in CKD patients with high risk of fracture.
- Conditions
- Chronic Kidney Diseases, Fracture, Bone Density, Low, End Stage Renal Disease
- Trial name
- NCT05692297
- Testing
- Denosumab, Non-denosumab
- Where
- China
- Volunteers
- 102 people
- Sponsor
- Capital Medical University
Low Bone Mineral Density, Postmenopausal Osteoporosis
Romosozumab (AMG 785) in Postmenopausal Women With Low Bone Mineral Density
The primary objective was to determine the effect of treatment with romosozumab versus placebo at month 12 on the percent change from baseline in bone mineral density (BMD) at the lumbar spine in postmenopausal women with low…
- Trial name
- NCT00896532
- Testing
- Alendronate, Teriparatide, Romosozumab
- Volunteers
- 419 people
- Sponsor
- Amgen
T2DM (Type 2 Diabetes Mellitus), Low-level Laser Therapy
Effect of Low-level Laser Therapy on Type II Controlled Diabetic Patients After Dental Implant Insertion
This study aimed therefore to evaluate bone density (BD) and OPG levels in the peri-implant crevicular fluid (PICF) in lased controlled type II Diabetes Mellitus (T2DM) patients versus non-lased T2DM patients.
- Conditions
- T2DM (Type 2 Diabetes Mellitus), Low-level Laser Therapy, Bone Density Increased
- Trial name
- NCT05279911
- Testing
- low-level laser therapy (LLLT)
- Where
- 5 sites in Egypt
- Volunteers
- 40 people
- Sponsor
- Sinai University
Low Bone Density
Stem Cell Recruitment in Osteoporosis Therapy
Osteoporosis is an important health problem in the rapidly-aging demographic. Fragility fractures are devastating consequences of osteoporosis.
- Trial name
- NCT01656629
- Testing
- Teriparatide, Alendronate, calcium and vitamin D
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- Johns Hopkins University
Low Bone Density, Osteopenia
Safety and Pharmacokinetics of Orally Administered Strontium L-Lactate in Healthy Adults
No clinical trials have evaluated strontium L-lactate (SrLac), the strontium salt of the L-enantiomer of lactic acid. Therefore, this clinical study was conducted to obtain general safety and pharmacokinetic (PK) information…
- Conditions
- Low Bone Density, Osteopenia, Osteoporosis, Postmenopausal
- Trial name
- NCT03761979
- Testing
- Strontium L-lactate
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- BioLink Life Sciences, Inc.
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Low Bone Mass, Low Bone Mineral Density
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
The purpose of this study is to assess how effective and safe denosumab is in a population of males with low bone mass at risk of fracture.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis, Osteopenia
- Trial name
- NCT00980174
- Testing
- 60 mg denosumab
- Volunteers
- 242 people
- Sponsor
- Amgen
Juvenile Osteoporosis, Low Bone Density
Alendronate in Juvenile Osteoporosis
The investigators earlier have shown that treatment of patients with juvenile osteoporosis with alendronate (Fosamax) for 12 months increased the bone density without side effects.
- Conditions
- Juvenile Osteoporosis, Low Bone Density, Fractures
- Trial name
- NCT00920075
- Testing
- Alendronate (Fosamax)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Medical University of South Carolina
Resting Metabolic Rate, Bone Mineral Density, Low, Susceptibility to
The Health of Competitive Fitness Athletes
Fitness athletes emphasize the value of staying lean, muscular and defined, and motivates and inspires followers through social media.
- Conditions
- Resting Metabolic Rate, Bone Mineral Density, Low, Susceptibility to, Body Image, Perfectionism
- Trial name
- NCT03007459
- Testing
- Psychological health, Physiological health
- Where
- Norway
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Norwegian School of Sport Sciences
Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women With Low Bone Mineral Density
An Open-label, Single-arm Extension Study to Evaluate the Long-term Safety of Denosumab Administration in Postmenopausal Women with Low Bone Mineral Density
- Trial name
- NCT00325468
- Testing
- AMG 162
- Volunteers
- 200 people
- Sponsor
- Amgen
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Infant, Extremely Low Birth Weight, Lung Diseases, Obstructive
Growth, Health and Development in Children Born Extremely Preterm
Background: In a national Norwegian cohort of children born before 28 weeks gestation or with a birth weight less than 1000 g born in 1999 and 2000, 372 survived.
- Conditions
- Infant, Extremely Low Birth Weight, Lung Diseases, Obstructive, Disorder of Bone Density and Structure, Unspecified, Cognition Disorders
- Trial name
- PEP11 (NCT01150071)
- Where
- 2 sites in Norway
- Volunteers
- 232 people
- Sponsor
- University of Bergen
Low Bone Mass, Low Bone Mineral Density
A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
To evaluate the combined effect of denosumab treatment and discontinuation on cortical thickness at the distal radius by High Resolution-Peripheral Quantitative Computed Tomography (HR-pQCT).
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00890981
- Testing
- high-resolution peripheral quantitative computed tomography (HR-pQCT), Dual energy X-ray absorptiometry (DXA), Denosumab
- Volunteers
- 79 people
- Sponsor
- Amgen
Multiple Sclerosis, Low Bone Density
Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis
The purpose of this study is to determine if certain drugs commonly used to treat multiple sclerosis have an effect on bone health.
- Trial name
- NCT00490906
- Testing
- Copaxone, Interferon-beta 1a, Interferon-beta 1b
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Nancy Hammond, MD
Low Bone Mass, Low Bone Mineral Density
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
To characterize the effects of discontinuation of denosumab therapy on variables of bone histology in postmenopausal women with low bone mass or osteoporosis.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Osteoporosis, Postmenopausal Osteoporosis
- Trial name
- NCT00887965
- Testing
- Previous denosumab
- Volunteers
- 15 people
- Sponsor
- Amgen
Low Bone Mineral Density, Osteopenia
A Multi-Center, Randomized, Open-Label Study to Assess the Immunogenicity and Safety of Denosumab in Pre-filled Syringe Compared to Vial in Subjects With Low Bone Mineral Density
The purpose of this study is to compare the immunogenicity profiles of denosumab pre-filled syringe (PFS) and vial at 6 months in postmenopausal women with low bone mineral density (BMD).
- Conditions
- Low Bone Mineral Density, Osteopenia, Osteoporosis
- Trial name
- NCT00515463
- Testing
- denosumab
- Volunteers
- 311 people
- Sponsor
- Amgen
Low Bone Mineral Density
Determine the Efficacy, Safety and Tolerability of Denosumab (AMG 162) in the Treatment of Postmenopausal Women With Low Bone Mineral Density
To determine the effect of denosumab treatment compared with placebo over 12 months on bone mineral density (BMD) of the lumbar spine in postmenopausal women with low BMD.
- Trial name
- NCT00043186
- Testing
- Denosumab, Alendronate
- Volunteers
- 412 people
- Sponsor
- Amgen
Crohn's Disease, Low Bone Mineral Density
Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's Disease
The occurrence of bone loss in Crohn's disease patients is an important clinical problem for both patients with and without active disease.
- Trial name
- NCT01215890
- Testing
- risedronate
- Where
- Canada
- Sponsor
- University of Alberta